Top Stories
Takeda shared additional Phase III data backing the use of oveporexton to treat narcolepsy type 1, while Pelago acquired a fellow Swedish CRO, RG Discovery.
The funds will also support late-stage development of nelivabon, an oral vasopressin V1b receptor antagonist.
Navacaprant failed to improve depressive symptoms in both the KOASTAL-2 and -3 studies.
SPY002 demonstrated a10.7-point reduction in RHI and meaningful clinical remission and endoscopic outcomes, according to the company.
The company cited encouraging data in lower-risk pancreatic cancer patients to justify next-stage testing for ELI-002 7P, its investigational AMP cancer immunotherapy.
Conference News
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% ...
FirstWord will be speaking with a leading expert about Phase III BRUIN CLL-322 data for Eli Lilly's Jaypirca, and where the non-covalent BTK inhibitor fits in the treatment algorithm for CLL.
Presentations will highlight the patient experience of cannabis withdrawal/cannabis use disorder and Phase 2 CAN-002 data for investigational PP-01 in adults with cannabis use disorderPHOENIXVILLE, Pa...
GOTHENBURG, SE / ACCESS Newswire / June 16, 2026 / IRLAB Therapeutics AB ((STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that a...
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
